HROW vs. HALO
Compare and contrast key facts about Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HROW or HALO.
Correlation
The correlation between HROW and HALO is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
HROW vs. HALO - Performance Comparison
Loading data...
Key characteristics
HROW:
1.56
HALO:
1.14
HROW:
2.76
HALO:
2.01
HROW:
1.33
HALO:
1.30
HROW:
1.33
HALO:
1.76
HROW:
3.70
HALO:
4.66
HROW:
33.22%
HALO:
12.84%
HROW:
88.78%
HALO:
44.78%
HROW:
-99.46%
HALO:
-74.26%
HROW:
-82.32%
HALO:
-6.09%
Fundamentals
HROW:
$895.12M
HALO:
$8.35B
HROW:
-$0.49
HALO:
$3.76
HROW:
4.48
HALO:
7.49
HROW:
12.42
HALO:
17.92
HROW:
$212.86M
HALO:
$1.08B
HROW:
$158.64M
HALO:
$887.05M
HROW:
$24.97M
HALO:
$530.80M
Returns By Period
In the year-to-date period, HROW achieves a -27.27% return, which is significantly lower than HALO's 37.77% return. Over the past 10 years, HROW has underperformed HALO with an annualized return of 11.89%, while HALO has yielded a comparatively higher 15.06% annualized return.
HROW
-27.27%
3.92%
-53.53%
110.34%
41.21%
11.89%
HALO
37.77%
14.16%
8.02%
52.65%
21.63%
15.06%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HROW vs. HALO — Risk-Adjusted Performance Rank
HROW
HALO
HROW vs. HALO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
HROW vs. HALO - Dividend Comparison
Neither HROW nor HALO has paid dividends to shareholders.
Drawdowns
HROW vs. HALO - Drawdown Comparison
The maximum HROW drawdown since its inception was -99.46%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HROW and HALO. For additional features, visit the drawdowns tool.
Loading data...
Volatility
HROW vs. HALO - Volatility Comparison
The current volatility for Harrow Health, Inc. (HROW) is 14.48%, while Halozyme Therapeutics, Inc. (HALO) has a volatility of 20.20%. This indicates that HROW experiences smaller price fluctuations and is considered to be less risky than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
HROW vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Harrow Health, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HROW vs. HALO - Profitability Comparison
HROW - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Harrow Health, Inc. reported a gross profit of 32.31M and revenue of 47.83M. Therefore, the gross margin over that period was 67.5%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a gross profit of 216.46M and revenue of 264.86M. Therefore, the gross margin over that period was 81.7%.
HROW - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Harrow Health, Inc. reported an operating income of -11.23M and revenue of 47.83M, resulting in an operating margin of -23.5%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported an operating income of 141.54M and revenue of 264.86M, resulting in an operating margin of 53.4%.
HROW - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Harrow Health, Inc. reported a net income of -17.78M and revenue of 47.83M, resulting in a net margin of -37.2%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a net income of 118.10M and revenue of 264.86M, resulting in a net margin of 44.6%.